Table 6 Nanoparticles in clinical trial for diagnosis or therapy of vascular aging-related diseases
From: Nanoparticles in the diagnosis and treatment of vascular aging and related diseases
Diseases | Nanoparticles | Cargos | Outcome/purpose | ClinicalTrials.gov Identifier | Phase |
|---|---|---|---|---|---|
Atherosclerosis | Silica-AuNPs | None | Reduce the total atheroma volume follow 12 months treatment | NCT01270139 | Completed |
64Cu-25%-CANF-Comb | None | Demonstrate feasibility of PET imaging of radiopharmaceutical nanoparticle 64Cu-25%CANF-Comb uptake by PET-MR | NCT02417688 | Phase 2 | |
LDE | Methotrexate | Evaluate the safety and efficacy of methotrexate-LDE in patients with stable coronary disease | NCT04616872 | Phase 2 | |
LDE | Paclitaxel | Evaluate the safety and efficacy of paclitaxel-LDE in patients with stable coronary disease | NCT04148833 | Phase 3 | |
PEG-liposome | Prednisolone | Continuous low-dosed anti-inflammatory drugs have great potential as novel treatment strategies | NCT01601106 | Phase 2 | |
MI | USPIOs | None | Hold major promise as a potential method for assessing cellular myocardial inflammation and left ventricular remodeling | NCT01323296 | Completed |
USPIOs | None | Examine the ability of USPIOs to image myocardial inflammation following acute MI | NCT01995799 | Phase 2 | |
Polymeric nanoparticles | BP-SES, DP-EES | Comparable safety and efficacy profiles of BP-SES and DP-EES were maintained throughout 2 years of follow-up | NCT01443104 | Completed | |
Ultra-sensitive nanoparticle | None | Improved analytical performance at very low concentrations of troponin | NCT00250471 | Phase 3 | |
Nanoemulsion | Methotrexate | Evaluate the effect of methotrexate carried in nanoemulsion on left ventricular remodeling after STEMI | NCT03516903 | Phase 2 | |
GQDs | None | Evaluate the sensitivity, precision, and effectiveness of photoelectrochemical immunosensor for early diagnosis of acute MI | NCT04390490 | NA | |
Coronary artery disease | SPIONs | None | Evaluate the accuracy and safety of coronary artery contrast-enhanced MRI With polysaccharide SPIONs | NCT05032937 | Phase 1 |
Liposome | Alprostadil | Observe the safety and tolerability of single/multiple-dose administration of different doses of Alprostadil Liposome for Injection as well as to confirm the safety dose range | NCT02889822 | Phase 1 | |
Vascular restenosis | Albumin-nanoparticles | Paclitaxel | Determine the appropriate dose of the new medicine for future trials | NCT 00093223 | Completed |
Albumin-nanoparticles | Paclitaxel | Investigate the use of systemic intracoronary administration of albumin-bound paclitaxel, ABI-007, for the prevention and reduction of restenosis | NCT00124943 | Phase 2 | |
liposomes | Alendronate | Reduce in-stent restenosis as compared to placebo | NCT00739466 | Completed | |
Chronic kidney disease | SPIONs | None | Explore the effectiveness and safety of polysaccharide SPIONs injection for contrast-enhanced renal artery magnetic resonance | NCT05045872 | Phase 1 |
liposomes | Iron | Evaluate the efficacy of treatment with liposomal oral iron compared to intravenous iron in chronic kidney disease anemic patients | NCT01864161 | Phase 4 |
